Welcome to our dedicated page for enGene Therapeutics SEC filings (Ticker: ENGNW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on enGene Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into enGene Therapeutics's regulatory disclosures and financial reporting.
enGene Therapeutics Inc. is asking shareholders to vote at a virtual-only annual general meeting on June 9, 2026. Holders of common shares at the April 28, 2026 record date can participate online, vote, and submit questions via live audio webcast.
Shareholders will vote on electing four directors to three-year terms and on appointing KPMG as auditors, with the board recommending “FOR” on both items. Quorum requires at least two persons representing at least 33⅓% of shares entitled to vote.
enGene Therapeutics Inc. reported updated interim results from the pivotal Cohort 1 of its Phase 2 LEGEND trial of detalimogene voraplasmid in high-risk, BCG-unresponsive NMIBC, and amended the employment agreement of Dr. Hussein Sweiti. Among 125 patients, detalimogene achieved a 54% complete response rate at any time and 43% at six months, with a low 3.2% progression rate to muscle-invasive or more advanced disease. Treatment-related adverse events occurred in 55% of patients, were mainly Grade 1–2, and led to dose interruptions or discontinuations in 2.4% of patients each. A Kaplan-Meier estimate showed a 12‑month complete response rate of 25%, and later-enrolling patients had lower response rates than earlier subgroups, which the company is further analyzing.
enGene Therapeutics Inc. holders led by Invus-related entities and Avicenna reported beneficial ownership positions in an amended Schedule 13G/A. As of March 31, 2026, Invus Public Equities directly held 4,513,228 shares and Avicenna Life Sci Master Fund directly held 739,931 shares. The filing states percentages based on 66,989,466 Shares outstanding as of March 3, 2026, with Invus Public Equities and related reporting persons shown at 6.7% and Mr. Raymond Debbane shown at 7.8%.
The cover and Item 4 describe control relationships among Invus Public Equities, Invus PE Advisors, Invus Global Management, Siren, Avicenna GP, Ulys and Mr. Debbane; each reporting person certifies the holdings were not acquired to change control. Signatures are dated May 5, 2026.
enGene Therapeutics Inc., formerly enGene Holdings Inc., has changed its corporate name to enGene Therapeutics Inc., effective April 8, 2026. The amendment affects only the name; no other changes were made to the company’s articles. The company’s common shares and warrants will continue trading on Nasdaq under the symbols ENGN and ENGNW, respectively.
In a related press release, enGene explained that the new name reflects its transition toward potential commercialization of its lead gene therapy detalimogene voraplasmid. The company plans a Biologics License Application submission for detalimogene in the second half of 2026, targeting potential approval and a commercial organization in 2027.
enGene Holdings Inc. entered a new sales agreement with Leerink Partners that allows it to sell common shares from time to time in an at-the-market offering for an aggregate offering price of up to $100,000,000 under its existing shelf registration.
Leerink Partners will act as sales agent and receive a commission of up to 3.0% of the gross proceeds, with no obligation for enGene to sell or for Leerink to place any shares. In connection with this new arrangement, enGene terminated its prior open market sale agreement with Jefferies LLC, under which no common shares had been sold.
enGene Holdings Inc. reported a larger quarterly net loss as it continues to invest heavily in its lead bladder cancer gene therapy, detalimogene. For the three months ended January 31, 2026, net loss was $29.8M, compared with $24.6M a year earlier, driven by higher research and development and general and administrative expenses.
To support development and potential commercialization, enGene significantly strengthened its balance sheet. Cash, cash equivalents and marketable securities rose to $312.5M from $202.3M at October 31, 2025, helped by a late‑2025 equity offering and a new term loan facility of up to $125M, of which $25M is drawn. The company believes this funding will cover operating and debt needs for at least the next 12 months as it advances its pivotal LEGEND trial and prepares a planned Biologics License Application in the second half of 2026.
enGene Holdings Inc. reported a first quarter 2026 net loss attributable to common shareholders of approximately $29.8 million, or $0.44 per share, compared with about $24.6 million, or $0.48 per share, a year earlier. Operating expenses rose to $31.2 million from $26.6 million, driven by higher research and development spending on the LEGEND trial and preparation for a planned Biologics License Application, as well as increased general and administrative costs to support public company operations. Cash, cash equivalents and marketable securities were $312.5 million as of January 31, 2026, supported by a $140.1 million underwritten offering completed in November 2025 and an expanded $125 million debt facility with Hercules Capital, giving an expected cash runway into the second half of 2028. Preliminary data from the LEGEND pivotal cohort in high-risk, BCG-unresponsive non-muscle invasive bladder cancer showed complete response rates of 63% at any time (n=62), 56% at 3 months (n=62), and 62% at 6 months (n=37), with a generally favorable tolerability profile and low rates of treatment-related dose interruptions and discontinuations.
enGene Holdings Inc. is registering an aggregate of $400,000,000 of securities under a shelf registration, which includes $150,500,276.03 of unsold securities previously registered under File No. 333-283201 pursuant to Rule 415(a)(6).
The prospectus lists the securities that may be offered from time to time — common shares, preferred shares, debt securities, subscription receipts, warrants and units — and states specific terms will be provided in prospectus supplements.
enGene Holdings Inc. filed Amendment No. 1 to its annual report to add the previously omitted Part III disclosures on directors, governance, executive compensation, ownership and auditor matters, and to update certain exhibits.
The amendment does not change prior financial statements and is meant to be read together with the original annual report. It details a nine‑member, majority‑independent, staggered board, outlines the roles of key committees, and describes the company’s code of conduct and insider trading policy. It also provides 2025 compensation data for the CEO, CFO and Chief Medical Officer and summarizes the 2023 Incentive Equity Plan, including stock option practices, severance terms and change‑of‑control treatment for equity awards.
enGene Holdings Inc. (ENGN) received an updated large-holder disclosure as Venrock-affiliated funds and related individuals reported beneficial ownership of 4,771,414 Common Shares, representing 7.1% of the company as of December 31, 2025.
The ownership is spread across Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., and related management entities, with Nimish Shah and Bong Y. Koh as voting members. The percentage is based on 66,984,661 Common Shares outstanding as of December 17, 2025. The group certifies the shares were not acquired to change or influence control of enGene.